The biopharma market is evolving rapidly. From the GLP‑1 surge to pricing reforms and the rise of advanced modalities, 2026 will challenge industry players to think strategically about revenue, margins, and market share. Companies that anticipate regulatory revisions, de-risk supply, and deliver tailored solutions will gain a clear competitive edge.
For biopharma leaders, the challenge is threefold: meeting unprecedented demand while minimizing risk, controlling costs, and navigating complex regulatory and supply-chain landscapes. Success in 2026 will favor those who partner with suppliers capable of delivering operational clarity, continuity, and tailored support, turning disruption into sustainable business growth.
The rapid rise of anti-obesity and diabetes therapies, led by next-generation oral GLP-1s and injectables, is reshaping the fundamentals of biopharma manufacturing. Beyond headline demand, these therapies introduce structural supply pressure, driven by material-intensive processes that dramatically increase requirements for solvents, intermediates, excipients, and specialty inputs; pressures that will only intensify as oral dosage forms scale.
“What we’re seeing is a shift from episodic sourcing to long-term supply strategy,” says Daniel Valentino, Global Sales Director at BrandNu. Drawing on more than 30 years of customer-centric leadership across the life sciences including building global account strategies, navigating complex supply negotiations, and scaling commercial models, Valentino brings a pragmatic lens to the challenge. As the subsidiary leading Caldic’s Biopharma business, BrandNu leverages this experience to align global sourcing, custom formats, and ready-to-use solutions, helping customers secure reliable access, manage cost, and meet accelerating market demand without compromising quality or continuity.
US and EU regulatory reforms, including the US Inflation Reduction Act and stricter rules around nitrosamines and PFAS, are reshaping the commercial landscape. Lou Avvisati, Senior Business Development Manager at BrandNu, highlights how his experience fostering long-term customer relationships in regulated markets helps customers stay ahead of evolving compliance demands:
“Compliance has become increasingly complex. Our collaborative approach empowers customers to stay ahead of evolving regulatory requirements by providing tailored solutions supported by comprehensive data packets and multi-compendial chemical options, all delivered with exceptional service. We offer the confidence that comes from partnering with a reliable provider, enabling customers to stay focused on bringing life-changing medicines and therapeutics to market.
At the same time, biopharma companies are entering a new phase of cost effectiveness. Following years of supply-chain volatility and inventory buildup, many organizations are reassessing the total cost of ownership: from sourcing and packaging to logistics, compliance, and waste reduction. Partners who can assist in simplifying operations while maintaining regulatory confidence and reliability of supply are critical to sustaining margins.
“Especially across procurement, supply chain and production, where real benefits can be realized by partnering with BrandNu,” confirms Lou, after joining the company in November 2025. Lou brings nearly 25 years of experience at a leading Fortune 500 company, managing regions across the Central U.S. and Canada. He has a strong track record in growing business in emerging markets, executing strategic plans, and facilitating operational efficiencies at the end-user level which delivers measurable customer value.
By anticipating evolving regulations and adjusting inputs accordingly, Caldic helps Biopharmaceutical companies maintain market access, protect margins, and avoid costly production disruptions.
Antibody-drug conjugates (ADCs) and cell & gene therapies (CGTs) present exciting opportunities and supply challenges. John Hodges, Business Development Manager who joined BrandNu in September 2025, explains how his cGMP and production-scale expertise acquired in prior roles is instrumental in supporting customers navigate across ADC and CGT supply challenges. “ADCs and CGTs are growing fast, and they bring supply challenges. The Caldic Biopharma offering includes cGMP-compliant chemical raw materials with full traceability, change notification, custom packaging & blending services, and dual-source options to mitigate single-sourcing risks. In short, we streamline operation efficiencies and reduce costs for our clients, allowing them to focus on innovation. By understanding exactly how our customers use these materials, we position ourselves as a partner that helps mitigate risk and accelerate production.”
“At, Caldic, we go beyond supplying high-purity raw materials and custom formulations. We deliver predictability, flexibility, and operational efficiency."
Daniel Valentino adds, “At, Caldic, we go beyond supplying high-purity raw materials and custom formulations. We deliver predictability, flexibility, and operational efficiency. By understanding exactly how our customers use their materials, we provide solutions that remove risk, reduce lead times, and improve yield. We take a proactive approach, mapping key brands, securing alternative sources, and preparing filing-ready packages so our customers can meet ambitious growth targets without disruption.”
Lou Avvisati emphasizes, “In today’s competitive biopharma market, continuity of supply is a strategic imperative. By combining deep process understanding with flexible, tailored solutions, we help our customers excel in their core operations and strengthen supply reliability. We enable them to focus on what they do best: bringing innovative therapies to market quickly, efficiently, and reliably. In 2026, success will favor those who anticipate market shifts, adapt quickly, and partner with suppliers who deliver more than just products. At Caldic, we deliver continuity.”
This customer-centric profile is increasingly recognized by leading global biopharma manufacturers, who view Caldic as a benchmark for service quality, transparency, and reliability. One of the top-ten global biopharma companies and BrandNu customers recognizes the company as the ‘gold standard’ among suppliers. From real-time communication to rapid resolution of quality events, excellent execution translates directly into reduced risk and greater confidence at scale, resulting in a top-tier ranking. A true testament to the unique care provided to partners, suppliers and customers alike, across Caldic subsidiaries worldwide.
Biopharmaceuticals are redefining patient care with targeted, life-saving therapies. At Caldic, we empower innovation in biologics, biosimilars, and advanced drug delivery systems by offering specialized ingredients, formulation support, and GMP-certified services tailored to meet global regulatory demands.
